March 6, 2012
Press release:
Mitsubishi Tanabe Pharma Corporation
Daiichi Sankyo Co., Ltd.
Daiichi Sankyo and Mitsubishi Tanabe Pharma Establish Strategic Allianceto Contribute to the Treatment of Diabetes in Japan
Companies conclude joint sales agreement for two treatments
for type 2 diabetes mellitus — MP-513 and TA-7284
Osaka and Tokyo, Japan (March 6, 2012) — Mitsubishi Tanabe Pharma Corporation (hereafter,Mitsubishi Tanabe Pharma; Head Office: Chuo-ku, Osaka; President and CEO: Michihiro Tsuchiya)
and Daiichi Sankyo Co., Ltd., (hereafter, Daiichi Sankyo; Head Office: Chuo-ku, Tokyo; President
and CEO: Joji Nakayama) have agreed to form a strategic sales alliance to conduct joint sales
activities for DPP4 inhibitor, MP-513 (generic name: teneligliptin), and SGLT2 inhibitor, TA-7284(generic name: canagliflozin), which are under development by Mitsubishi Tanabe Pharma in Japanfor the treatment of type 2 diabetes mellitus.
MP-513, a DPP4 inhibitor and TA-7284, a SGLT2 inhibitor, which were both discovered byMitsubishi Tanabe Pharma, are oral treatments for type 2 diabetes mellitus. MP-513 and TA-7284
have different mechanisms of action. In Japan, Mitsubishi Tanabe Pharma filed an NDA for MP-513 inAugust 2011, and TA-7284 is currently in phase 3 clinical trials with plans calling for an NDA
expected to be filed in 2013.
Mitsubishi Tanabe Pharma and Daiichi Sankyo will conduct joint sales activities for these drugs undera one-brand, two-channel framework. Moreover, the companies will implement new types of joint
sales activities, with detailed drug product information provided through mutual visits to medicalinstitutions. In the diversifying market for diabetes treatment agents, these activities will enable thecompanies to build a dynamic, cooperative sales system. This system will leverage the companies'combined marketing capabilities, which will be among the strongest in Japan, and facilitate thedetailed, sufficient, yet rapid, provision of accurate usage information and the proposal of treatments.
Through this strategic alliance, Mitsubishi Tanabe Pharma and Daiichi Sankyo will provide newtreatment options for type 2 diabetes mellitus and support for patients dealing with diabetes.
For more information about MP-513 and TA-7284, please see the attachment.

For further information, please contact:
Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department
TEL：06-6205-5211

Daiichi Sankyo Co., Ltd.
Corporate Communications Department
Media, please contact: TEL：03-6225-1126
Capital markets, please contact: TEL：03-6225-1125-1-

<Attachment>

MP-513MP-513 inhibits the function of dipeptidyl peptidase-4 (DPP-4), which selectively decomposes
glucagon-like peptide-1 (GLP-1), a hormone secreted from the gastrointestinal tract in response tofood intake. In this way, MP-513 promotes insulin secretion and suppresses glucagon secretion,
thereby controlling blood glucose levels. MP-513 has the distinctive feature of being unlikely tocause hypoglycemia and unwanted weight gain, which have been problems with conventional
diabetes treatments. With its potent and sustained action, MP-513 is expected to be effective inameliorating hyperglycemia with once-a-day oral administration. MP-513's renal excretion rate islow, so it is possible that it will not be necessary to adjust the dosage for patients with impaired renal
function.

TA-7284
TA-7284 inhibits SGLT2 (sodium-glucose transporter-2), which is involved in the reabsorption ofglucose in the renal tubules, thereby promoting the excretion of glucose in the urine and reducing
blood sugar. In this way, TA-7284 has a new mechanism of action that does reduce blood sugar
through an entirely different mechanism that does not work through insulin. In addition to its strong
blood glucose lowering effect, it is expected to have a low hypoglycemia risk as well as a weight
reduction effect that is not seen with other oral diabetes treatments.

-2-